TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 0.800nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.20nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.40nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.70nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 1.70nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.10nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.20nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.60nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 2.90nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.10nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.30nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.40nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 3.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.20nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.30nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.30nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.40nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.40nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.60nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.70nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 4.90nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 5.30nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 5.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 5.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 5.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 6.10nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 6.20nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 6.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.10nMAssay Description:Cell viability was determined using the Cell Titer Glo assay (Promega) as previously described. Briefly, 2000-3000 cells per well were plated in 384-...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.5nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.60nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 7.80nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 8nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 8.20nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 8.40nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 8.90nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 9nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 9nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair
TargetReceptor tyrosine-protein kinase erbB-2 [1-775,'YVMA',776-1255](Homo sapiens (Human))
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Dizal (Jiangsu) Pharmaceutical Co.
US Patent
Affinity DataIC50: 9.30nMAssay Description:The inhibition activity and the selectivity of the compounds against mutant EGFR and WT EGFR were assessed by using WT EGFR cell line A-431 (American...More data for this Ligand-Target Pair